American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book.

YONKERS, N.Y. -- Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, announced today that new information on AVR118 has been accepted for publication in the 2007 Proceedings of the American Society of Clinical Oncology (ASCO) Abstract publication. This publication will be distributed to the nearly 25,000 oncology practioners who will be attending this year's meeting in Chicago on June 1-5.

Based on recent work conducted by ADVR, new insight has been made regarding the chemical composition of AVR118. As a result of these findings, clinicians will have a better understanding of how AVR118 exerts its clinical effects, whether it is administered topically or systemically. Additionally, this work may provide clues on how new formulations of AVR118 may be produced with greater activity in a variety of different clinical applications.

"Based on our new understanding of how AVR118 exerts its cytoprotective effects, we are in a much better position to understand how it might be used more effectively to stimulate appetite, improve fatigue, and assist in rapidly reversing the toxic side-effects of chemo, radiation and possibly even interferon therapies. We now have evidence that it binds to adenosine receptors in-vitro and increases cAMP release in several different cell lines. Its anti-anorexic activity may involve targeted receptor binding in the gut and in the functional pathway of orexin A. AVR118 has also shown a 20% enhancement of epitheliazation when compared to saline controls in a controlled porcine wound healing model" says, Dr. J. T. D'Olimpio, author of the abstract.

"Based on our improved understanding of the composition of AVR118, we are in a much better position to predict the potential clinical indications for our product," says Stephen M. Elliston, CEO and President of Advanced Viral Research Corp. "Up until now there has been a major unmet need for new non-toxic orexigenic and cytoprotective agents that can ameliorate some of the intractable symptoms associated with cancer related cachexia. Today, we are increasingly optimistic that AVR118 might provide a much needed alternative to existing therapies," added Elliston.

Advanced Viral Research Corp. is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models.

Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy.

Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by the Company. AVR118 (Product R) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. There is no assurance that the Company will be able to secure the financing necessary to continue and/or complete the clinical trials of AVR118 or satisfy certain other conditions relating to clinical trials including obtaining adequate insurance on terms acceptable to the Company or that if completed, clinical trials will assist the Company in obtaining FDA or other regulatory approval. The Company undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

For further information regarding Advanced Viral Research Corp., please Visit our website at http://www.adviral.com.